📜N-Ethoxycarbonyl-N-(Pyridin-2-yl)-4-Ethoxy-Carbonyloxy-2-Methyl-2H-1,2-Benzothiazine-3-Carboxamide 1,1-Dioxide 以 吡啶,水 作为反应溶剂,化学反应生成 屈昔康 参考文献:Benzothiazine Derivatives And Their Applications As Medicinal Products 标题:Benzothiazine Derivatives And Their Applications As Medicinal Products 摘要:该发明涉及与一般式i对应的化合物,其中:R.Sup.1代表一个较低的烷基基团(具有一到四个碳原子),苯基或苄基.这些化合物可用作药用产品或药用产品的合成中间体.
专利号:US-2012177593-A1 优先权日:2009-07-20 标 题 :Synthesis of dendrimer conjugates 发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH 权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN 摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.
专利号:US-8546532-B2 优先权日:2008-04-17 标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders 发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS 权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC 摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.
专利号:US-9051302-B2 优先权日:2008-01-15 标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents 发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN 权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG 摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
专利号:US-2024287041-A1 优先权日:2021-05-20 标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms 发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN 权利人:KARYOPHARM THERAPEUTICS INC 摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.
专利号:US-6593347-B2 优先权日:1998-10-30 标题 :Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use 发明人:BANDARAGE UPUL K; DONG QING; FANG XINQIN; GARVEY DAVID S; MERCER GREGORY J; RICHARDSON STEWART K; SCHROEDER JOSEPH D; WANG TIANSHENG 权利人:NITROMED INC 摘要:The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.
专利号:US-2015352230-A1 优先权日:2013-01-11 标 题:Synthesis and isolation of dendrimer based imaging systems 发明人:MULLEN DOUGLAS GURNETT; BAKER JR JAMES R; BANASZAK HOLL MARK M; HUANG BAOHUA; DOUGHERTY CASEY; BALL JACK 权利人:UNIV MICHIGAN 摘要:The present invention relates to novel methods of synthesis and isolation of antibodies conjugated with modular dendrimer nanoparticles. In particular, the present invention is directed to antibodies conjugated with novel modular dendrimer nanoparticles having precise numbers of imaging agents, methods of synthesizing the same, compositions comprising such antibodies conjugated with such modular dendrimer nanoparticles, as well as systems and methods utilizing the conjugates (e.g., in imaging settings) (e.g., in diagnostic and/or therapeutic settings) (e.g., for the delivery of therapeutics, imaging, and/or targeting agents).
1: Esteve J, Farré AJ, Roser R. Pharmacological profile of droxicam. Gen Pharmacol. 1988;19(1):49-54. doi: 10.1016/0306-3623(88)90004-3. 11(4):10-4. 11(4):3-9. 194(3):170-2. Spanish. 32(12):1115-9. 36(4):318-20. doi: 10.1111/j.1365-4362.1997.tb03059.x. 88(1):49-52. Spanish. 29(8):739-45. doi: 10.1002/j.1552-4604.1989.tb03409.x. 8(7):423-9. 20(4):275-9. doi: 10.1007/BF03190244. 8(7):407-22. 11(4):29-34. 84(4):276. Spanish. 40(1):104-5. doi: 10.1111/j.1365-2125.1995.tb04547.x. 15: Rodríguez-de-la-Serna A, Geli-Ferrer C, Diaz-López C, Sánchez-García J. Comparative double-blind study of droxicam (new NSAID) versus indomethacin in rheumatoid arthritis. Eur J Rheumatol Inflamm. 1991;11(4):35-44. 29(4):617-24. doi: 10.1016/s0731-7085(02)00041-9. 11(4):50-8. 36(1):157-62. doi: 10.1016/j.jpba.2004.04.018. 83(2):138-9. Spanish. 11(4):21-8.
合成参考文献
摘要:Cancelo Suárez P, Prieto de Paula JM, de la Cueva Gallo JA, Velasco Osés A. [Toxic hepatitis caused by droxicam]. Med Clin (Barc). 1992 Jul 04;99(6):238–9. 摘要:Caballería Rovira E, Aragó López JV, Massó Ubeda RM, Sanchís Closa A. [Toxic hepatitis caused by droxicam]. Med Clin (Barc). 1992 Jul 04;99(6):239. 摘要:Rosselló T, Fiol F. [Toxic hepatitis caused by droxicam]. Med Clin (Barc). 1992 Jul 04;99(6):239.